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AIMS/HYPOTHESIS  
There is considerable variability in how diabetes progresses after diagnosis.  Progression 
modelling has largely focused on ‘time to failure’ methods, yet determining a ‘coefficient of 
failure’ has many advantages.  We derived a rate of glycaemic deterioration in type 2 diabetes, 
using a large real-world patient cohort, and aimed to investigate the clinical, biochemical and 
immunological parameters associated with fast and slow rates of glycaemic deterioration. 
METHODS 
We utilised the electronic medical records from patients in the Genetics of Diabetes Audit and 
Research (GoDARTS) cohort. A model was derived based on a patient’s observed HbA1c 
measures from first eligible HbA1c after diabetes diagnosis through to study end (defined as 
insulin initiation, death, leaving area or end of follow-up). Each HbA1c measure was adjusted 
time-dependently for the effects of non-insulin antidiabetic drugs, changes in BMI and 
prednisolone use. The presence of LADA was defined as GAD titres >97.5th centile of the 
population distribution. 
RESULTS 
The mean glycaemic deterioration for patients with type 2 diabetes and LADA were 
0.13(95%CI 0.12,0.14)% and 0.26(0.21,0.32)% HbA1c per year respectively. A younger age of 
diagnosis and lower HDL were independently associated with higher rates of glycaemic 
deterioration.  The rate of deterioration in those diagnosed over 70 years of age was very low; 
with 66% having a rate of deterioration less than 0.1% HbA1c per year, and only 1.5% 
progressing more rapidly than 0.4% HbA1c per year.   
CONCLUSIONS/INTERPRETATION 
  
We have developed a novel approach to model diabetes progression in observational data 
across multiple drug combinations. This approach highlights how glycaemic deterioration in 
those diagnosed over 70 years of age is minimal supporting a stratified approach to diabetes 
management. 
  
  
INTRODUCTION 
Type 2 diabetes (T2DM) is a progressive disease, primarily characterised by beta cell failure 
[1, 2]. This progression is manifested clinically by HbA1c deterioration over time, despite 
lifestyle and increased pharmacologic intervention. However, the rate at which diabetes 
progresses is highly variable between patients. Some patients have a rapid deterioration and 
advance to insulin therapy quickly whilst others can be adequately treated with non-insulin 
antidiabetic medication in excess of 20 years. Gaining insight into why some patients progress 
rapidly and some do not will enable a more stratified approach to the management of T2DM 
by identifying patient subgroups who may require different management depending on their 
likelihood of diabetes progression. 
Previous studies have investigated factors associated with the rate of diabetes progression. 
However, these studies have only reported an outcome based on progression to antidiabetic 
medications (i.e., time to initiation of non-insulin antidiabetic medication, failure of 
monotherapy or time to insulin) [1, 3-9]. In these studies, younger age at diagnosis and 
insufficient beta cell function were consistently associated with faster diabetes progression. 
UKPDS reported that presence of positive GAD antibody concentrations predicted an increased 
likelihood of insulin requirement [3]. Other less well established associations were female sex, 
low BMI (defined as less than 30kg/m2), weight gain, lower HDL and higher serum creatinine. 
In addition, we have previously reported that risk of progression, as defined by requirement of 
insulin treatment, is associated with normal weight or obesity (U-shaped relationship), and 
higher triglyceride and lower HDL levels [6]. 
The studies outlined rely on defining an endpoint, such as a glycaemic threshold, or starting a 
new drug.  These ‘time to failure’ approaches are problematic, particularly in the real-world 
where decisions to start a drug are subject to prescriber or patient inertia, and where fluctuations 
  
in HbA1c, e.g. due to lifestyle change, can trigger a failure event.  A ‘coefficient of failure’ 
measure was proposed to avoid these difficulties – in essence, deriving a rate of glycaemic 
deterioration for each patient [10]. This approach was applied to the UKPDS study, reporting 
a coefficient of failure of 0.34% (3.7mmol/mol) per year with chlorpropamide treatment [10], 
and to the ADOPT study where a rate of glycaemic deterioration of 0.14% (1.5mmol/mol) 
HbA1c per year in the metformin monotherapy arm was described [11]. However, to our 
knowledge, no studies are reported describing the coefficient of failure in settings outwith these 
clinical trials of monotherapy.  Determining rates of deterioration in a population over time is 
challenging as underlying disease severity reflects not only observed HbA1c, but also lifestyle 
and pharmacologic interventions.  
The aim of this study was to derive a model for the rate of deterioration of T2DM (coefficient 
of failure) in a large population-based cohort and to investigate the clinical, biochemical and 
immunological characteristics associated with fast and slow rates of glycaemic deterioration. 
  
  
METHODS 
An observational cohort study was performed using comprehensive electronic medical records 
from patients in the Genetics of Diabetes Audit and Research (GoDARTS) database, which has 
been described previously [12, 13]. In short, this contains detailed information on all encashed 
prescriptions from 1994 onwards in Tayside, Scotland, as well as all biochemistry and BMI 
measures. So, for each patient we have a comprehensive longitudinal record of diabetes therapy 
and glycaemic control.  
The GoDARTS study was approved by the Tayside Committee on Medical Research Ethics, 
and informed consent was obtained from all patients (REC reference 053/04). 
The GoDARTS cohort and the research question outlined here were studied as part of the 
Diabetes Research on Patient Stratification (DIRECT) study, an EU FP7 Innovative Medicines 
Initiative (see www.direct-diabetes.org) project. 
Study Population 
Diabetes diagnosis was defined as date of first HbA1c ≥6.5% (48mmol/mol) (based on the 
recommended cut-off point for diagnosing diabetes) or first prescription for antidiabetic 
medication, following a clinical diagnosis of T2DM. Patients were followed from diagnosis 
until insulin initiation, death, leaving the area or end of follow-up (30th September 2015), 
whichever came first. To ensure sufficient prescribing information and longitudinal HbA1c and 
BMI measurements, patients had to have been diagnosed with diabetes on or after 1st January 
1994 to be eligible for the study. Patients who progressed to insulin within one year of diagnosis 
were excluded from the current analysis to minimise inclusion of patients with type 1 diabetes. 
  
  
GAD antibodies 
GAD antibodies were measured at the time of recruitment into GoDARTS, allowing us to 
define a subgroup of patients who were ‘GADA positive’ (defined as ≥11U/L (97.5th centile)) 
with latent autoimmune diabetes in adults (LADA), whom we would expect to have a more 
rapid diabetes progression, with different clinical covariates associated with progression 
compared to patients with T2DM [3].  
Study criteria:  
The underlying assumption of our progression model is that change in HbA1c over time is 
linear, and this is supported by the Belfast Diet Study which reported two linear phases pre and 
post diagnosis of diabetes [1].  Some patients who had a high HbA1c at diagnosis and 
subsequent marked improvement in HbA1c, reflecting likely glucose toxicity at presentation, 
did not fulfil this assumption of linearity.  Therefore for all patients we restricted the starting 
HbA1c value to an upper limit of 8% (64mmol/mol), and allowed one year from diagnosis to 
reach this target HbA1c level. 
The first HbA1c measure satisfying the inclusion criteria was defined as the study start for that 
patient. Two subsequent HbA1c measurements were required for a patient to be included in the 
analysis. In addition, patients were required to have a BMI measurement at diagnosis (defined 
as the average value +/- one year from diabetes diagnosis) and at least two subsequent BMI 
measures during the follow-up period. A small number of patients were also excluded during 
the analysis as they had fewer than three HbA1c and/or BMI measures after outlying data points 
were removed (described later). 
  
  
Outcome: 
A model was derived for each patient’s glycaemic deterioration rate based on observed HbA1c 
measures from the first eligible HbA1c through to study end.  
HbA1c measures were adjusted time-dependently for: 
1. Non-insulin antidiabetic drugs: untreated measures were the reference group, defined 
as measures prior to antidiabetic drug initiation. As metformin was the most commonly 
prescribed antidiabetic drug and we expected to observe a dose-dependent relationship 
with HbA1c [14], we divided daily dose into five groups (<1g, ≥1g to <1.5g, ≥1.5g  to 
<2g, 2g, and >2g). The other antidiabetic drugs were grouped solely by drug class either 
because there was no evidence of a dose-dependent relationship with HbA1c (as is the 
case for sulphonylureas) or the limited number of measures would result in multiple, 
small groups (as is the case for thiazolidinediones, acarbose, glucagon-like peptide 
agonists, dipeptidyl peptidase-4 inhibitors, glinides and SGLT2 inhibitors). 
Antidiabetic drugs were further grouped into monotherapy, and combinations of dual 
and triple therapy.  
2. BMI change: expressed as percentage change from BMI at diagnosis and categorised 
as: no change (reference group), any weight gain, and weight loss divided into five 
groups (<2.5%, 2.5 to 5%, 5 to 7.5%, 7.5 to 10%, and >10%).  
3. Glucocorticoid use: a widely recognised side effect of glucocorticoids is to raise HbA1c 
temporarily [15], and as a significant proportion of patients were prescribed 
prednisolone during the study period, we adjusted HbA1c measures accordingly 
(categorised as ‘yes’ or ‘no’) . 
  
  
Covariates: 
The following covariates were included in the model: age at diabetes diagnosis, gender, and a 
variable indicating presence of glucose toxicity at diagnosis (i.e. initial HbA1c>8% 
(64mmol/mol)). BMI, HDL and triglycerides were also included, defined as the average of all 
measures +/- one year from diagnosis.  
Statistical Analysis: 
A linear mixed effects model was fitted. As the time intervals between HbA1c measurements 
are more or less unique to each patient, the ‘continuous time/continuous space’ spatial data 
covariance structure provided within the PROC MIXED procedure in SAS was utilised to 
describe the covariance structure among the errors.  
We began by fitting a model with both fixed and random intercept and slope, and adjustment 
for non-insulin antidiabetic drugs, prednisolone use and changes in BMI over time, fitted as 
fixed effects. The studentised residuals were examined and any HbA1c measures more than 
three standard deviations from the mean were removed as these values were considered likely 
outliers for that patient. 
We then ran the model again for T2DM and LADA patients separately and compared the 
individual patient glycaemic deterioration rates. These were calculated by adding together each 
patient’s random slope with the population average (fixed) slope.  
The model was then expanded in T2DM patients only, due to small numbers in the LADA 
group, to include the baseline clinical covariates of interest. To model the effect of each 
covariate on glycaemic deterioration, an interaction term between the covariate and time was 
included. We fitted univariate models in which baseline covariates were added singly, and a 
multivariate model that included all univariately significant covariates together. Age at 
diagnosis was split into four age bands (<50, 50 to 60, 60 to70 and >70 years), BMI was split 
  
into five categories based on WHO definitions (<25, 25 to 30, 30 to 35, 35 to 40 and >40 
kg/m2). HDL and triglycerides were split into four clinically meaningful bands (HDL: <1, 1 to 
1.2, 1.2 to 1.4 and >4; triglycerides: <1.5, 1.5 to 2.5, 2.5 to 3.5, and >3.5 mmol/L), with an 
additional ‘missing’ group created to avoid excluding patients with missing values from the 
multivariate model.  
All analyses were performed using SAS 9.4 and P<0.05 was considered statistically significant 
in all analyses. 
  
RESULTS 
Patient characteristics 
From a total of 6531 patients who did not progress to insulin within one year of diagnosis, 5488 
(84%) met the study inclusion criteria. A detailed flow chart of the study population derivation 
is presented in supplementary figure 1.  The median (IQR) study follow up time was 
9.4(6.2,12.4) years and the median (IQR) number of HbA1c and BMI measures per patient was 
21(14,29) and 20(13,29) respectively. A total of 121,926 HbA1c measures were generated in 
the 5488 patients.  A comparison of characteristics of patients included and excluded in the 
study is presented in supplementary table 1. Patients excluded from the study were younger, 
with higher BMI, lower HDL, higher triglycerides and higher HbA1c at diagnosis. In addition, 
there were higher proportions of patients with LADA and/or who had progressed to insulin 
therapy by the end of the study period.  As expected LADA patients were diagnosed younger 
with a lower BMI than patients with T2DM. 
Linear mixed model derived effects 
The linear mixed model included 112 different drug combinations as fixed effects. These 
represent the model derived estimates for HbA1c reduction by a particular drug combination 
compared to no treatment.  The drug effects for the most commonly prescribed combinations 
(defined as more than 500 measures) are presented in supplementary table 2. There was a total 
of 28,309(23.2%) untreated measures from 3736(68%) patients. We observed a dose-
dependent relationship with metformin with less than 1 gram per day lowering HbA1c by 
0.07(0.03,0.11)% (0.80(0.3,1.2)mmol/mol) and more than 2 grams lowering HbA1c by 
0.50(0.46,0.55)% (5.5(5.0,6.0)mmol/mol) on average. A total of 4557(4%) of HbA1c measures 
were whilst on prednisolone. The effect of prednisolone was to increase HbA1c by 
0.30(0.27,0.33)% (3.3(3.0,3.6)mmol/mol) on average (data not shown).  
  
The BMI effects derived from the model are presented in supplementary table 3. The 
coefficient presented is the effect of BMI change from baseline on HbA1c with no change as 
the reference group. For example, the effect of a 10% BMI reduction was to reduce HbA1c by 
0.40(0.36,0.43)% (4.4(3.9,4.7)mmol/mol) on average.  
Rates of glycaemic deterioration in T2DM and LADA 
The model derived patient glycaemic deterioration rate is the rate of change of HbA1c per year 
after adjusting for the effect of drug treatment and BMI change.  The distribution of the 
patients’ glycaemic deterioration rate is presented in figure 1, with patients with T2DM 
(n=5342) and LADA (n=146) presented separately. The mean (95% CI) coefficient of failure 
for patients with T2DM was 0.13(0.12,0.14)% (1.4(1.3,1.5)mmol/mol) per year. By 
comparison, the coefficient of failure for patients with LADA was approximately twice as rapid 
at 0.26(0.21,0.32)% (2.8(2.3,3.5)mmol/mol) per year. 
Clinical characteristics associated with glycaemic deterioration in T2DM 
To investigate what clinical covariates other than GADA positivity are associated with 
glycaemic deterioration, we expanded the model to include interaction terms between baseline 
clinical covariates and time within the T2DM group. The results for the overall model are 
presented in table 1. In the univariate analyses, younger age, male gender, glucose toxicity at 
presentation, higher BMI, lower HDL and higher triglycerides were all associated with higher 
rate of glycaemic deterioration. However, in the multivariate model, only younger age at 
diagnosis and lower HDL were independently associated with higher rate of glycaemic 
deterioration: Patients diagnosed younger than 50 deteriorated 0.15(0.13,0.17)% 
(1.6(1.4,1.9)mmol/mol) HbA1c per year faster than patients diagnosed over 70; and patients 
with an HDL less than 1mmol/L deteriorated 0.03(0.01,0.04)% (0.3(0.1,0.4)mmol/mol) per 
year faster than patients with an HDL greater than 1.4mmol/L.   The lack of independent 
  
association of BMI, higher triglyerides and glucose toxicity with rate of glycaemic 
deterioration in the multivariate model is likely due to the fact that these variables are all highly 
correlated, as seen in table 2.  Young patients (diagnosed under 50) are significantly more 
obese, with higher baseline HbA1c and triglycerides than older patients (diagnosed over 70).   
To further investigate the relationship between younger age at diagnosis and higher rates of 
glycaemic deterioration, the mean (95% CI) coefficient of failure grouped by five-year age 
bands for patients with T2DM is presented in figure 2. Of the patients diagnosed under 50, 15% 
had a glycaemic deterioration rate of greater than 0.4% (4.4mmol/mol) per year, compared with 
1.5% of the patients diagnosed over 70. Conversely 66% of the patients diagnosed over 70 had 
a glycaemic deterioration rate less than 0.1% (1.1mmol/mol) per year compared with just 24% 
of the patients diagnosed under 50.  
 
 
 
 
 
  
  
DISCUSSION 
In this large, observational, population-based study with a maximum follow-up period of over 
20 years, we have applied a novel approach to modelling diabetes progression. We have shown 
that in a real-world setting the underlying mean coefficient of failure (rate of glycaemic 
deterioration) in patients with T2DM is 0.13(0.12,0.14)% (1.4(1.3,1.5)mmol/mol) HbA1c per 
year and in patients with LADA it is faster, with a mean rate of 0.26(0.21,0.32)% 
(2.8(2.3,2.5)mmol/mol) HbA1c per year. Furthermore, our results suggest that patients with 
T2DM who deteriorate the fastest are those diagnosed under 50 years old and there is very 
limited deterioration in those diagnosed over the age of 70.  
We report a coefficient of failure in patients with T2DM comparable to that of the ADOPT 
clinical trial, which reported a 0.14% (1.5mmol/mol) annual rate of deterioration in HbA1c in 
a metformin monotherapy cohort [11]. Moreover, we know from UKPDS that GADA 
positivity is a strong predictor of diabetes progression [3], and here we have shown that patients 
with LADA progress approximately two times faster than patients with T2DM.  
Our findings are in accordance with other studies that reported the association between younger 
age at diagnosis and faster progression of diabetes [1, 4-8]. Patients diagnosed younger than 
50 progress rapidly compared with patients diagnosed over the age of 70 (figure 2), suggesting 
patients diagnosed younger may benefit from being treated more aggressively with earlier 
initiation of antidiabetic medications, particularly if future therapies can be established to delay 
progression. Conversely, diabetes diagnosed in a high proportion of older people progresses at 
a negligible rate and this is consistent with the need for less aggressive treatment targets in 
these patients.  The finding that in the real-world, 66% of patients with T2DM diagnosed after 
the age of 70 progress at a rate less than 0.1% (1.1mmol/mol) per year, and that only 1.5% 
progress at a rate more than 0.4% (4.4mmol/mol) per year is striking and highlights how 
  
glycaemic monitoring and management in those diagnosed over 70 years does not need to be 
so aggressive as those diagnosed under 50 years of age.  
Low HDL is commonly observed in patients with T2DM and has been previously shown to be 
associated with progression of diabetes [6, 9]. In this study we replicate those findings:  in the 
overall, multivariate model, apart from younger age at diagnosis, lower HDL is the only other 
independent predictor of progression in patients with T2DM.  
The aim of this study was to derive a ‘rate of deterioration’ or ‘coefficient of failure’, which 
we believe has many advantages over a time to failure model.  However there are a number of 
assumptions made and requirements of the data in order to develop this model.  Firstly we 
assume a linear deterioration in HbA1c.  This is supported by the Belfast Diet Study which 
reported two linear phases pre and post diagnosis of diabetes [1], however, there may be 
patients who do not follow this linear decline who are not well accounted for in our model.  
Secondly, the patients who do not make it into the model largely do so because they have a 
high HbA1c at diagnosis that does not fall below 8% within the first year, a requirement for 
inclusion in our model, or because they have too few HbA1c measures before they progress 
onto insulin.  As such our model excludes those with the most aggressive disease and/or those 
who present late with a high HbA1c, and focuses on those diagnosed close to diabetes onset or 
with less aggressive disease.  As such our coefficients of failure are likely to under-estimate 
the true progression rate in the population.  Thirdly the fact that we are studying real world 
clinical patients means that we lack some key measures that may be important for glycaemic 
deterioration, such as measures of beta-cell function and insulin resistance.   
In summary, we have developed a novel approach to model the coefficient of failure in 
observational data across multiple drug combinations. This approach can be used to investigate 
biological determinants of progression as well as the impact of different diabetes and non-
  
diabetes drugs on glycaemic deterioration.  We confirm that GADA are associated with greater 
glycaemic deterioration, and for the first time quantify the rate of glycaemic deterioration in 
the elderly.  Our findings of minimal glycaemic deterioration in this elderly onset group has 
important implications for stratifying diabetes care, suggesting less intensive glycaemic 
monitoring and management is required for this patient group.     
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Table 1: Differences in estimated glycaemic deterioration rates in patients with type 2 
diabetes  
  Univariate Analysis Multivariate Analysis 
 n Unadjusted Coefficient  
(95% CI)* 
P-value Adjusted Coefficient  
(95% CI)** 
P-value 
Age (years): 
<50 
50-60 
60-70 
>70 
 
1430 
1820 
1269 
823 
 
0.16(0.15 to 0.18) 
0.08(0.07 to 0.10) 
0.04(0.02 to 0.05) 
REF 
 
<0.0001 
<0.0001 
<0.0001 
 
 
0.15(0.13 to 0.17) 
0.08(0.06 to 0.09) 
0.03(0.02 to 0.05) 
REF 
 
<0.0001 
<0.0001 
<0.0001 
 
Gender: 
Males 
Females 
 
3013 
2329 
 
0.01(0.001 to 0.02) 
REF 
 
0.0289 
 
0.003(-0.01 to 0.01) 
REF 
 
0.5221 
Glucose toxicity: 
No 
Yes 
 
3574 
1768 
 
REF 
0.02(0.01 to 0.03) 
 
 
0.0019 
 
REF 
0.01(-0.003 to 0.02) 
 
 
0.1508 
BMI (kg/m2): 
<25 
25-30 
30-35 
35-40 
>40 
 
533 
1890 
1703 
774 
442 
 
REF 
0.01(-0.01 to 0.03) 
0.03(0.01 to 0.05) 
0.04(0.01 to 0.06) 
0.08(0.06 to 0.10) 
 
 
0.3928 
0.0030 
0.0008 
<0.0001 
 
REF 
-0.01(-0.02 to 0.01) 
0.001(-0.02 to 0.02) 
-0.01(-0.03 to 0.01) 
0.02(-0.004 to 0.04) 
 
 
0.4969 
0.9224 
0.5388 
0.1063 
HDL(mmol/L): 
<1 
1-1.2 
1.2-1.4 
>1.4 
Missing 
 
1275 
1524 
1168 
1119 
256 
 
0.06(0.04 to 0.07) 
0.04(0.02 to 0.05) 
0.01(-0.001 to 0.03) 
REF 
-0.001(-0.02 to 0.02) 
 
<0.0001 
<0.0001 
0.0615 
 
0.9266 
 
0.03(0.01 to 0.04) 
0.02(0.005 to 0.03) 
0.003(-0.01 to 0.02) 
REF 
-0.01(-0.03 to 0.02) 
 
0.0012 
0.0099 
0.6598 
 
0.4104 
Trigs (mmol/L): 
<1.5 
1.5-2.5 
2.5-3.5 
>3.5 
Missing 
 
790 
1391 
858 
819 
1484 
 
REF 
0.01(-0.01 to 0.02) 
0.02(-0.003 to 0.03) 
0.03(0.02 to 0.05) 
-0.003(-0.02 to 0.01) 
 
 
0.4238 
0.1003 
0.0003 
0.7292 
 
REF 
-0.001(-0.02 to 0.02) 
-0.002(-0.02 to 0.02) 
0.001(-0.02 to 0.02) 
0.005(-0.01 to 0.02) 
 
 
0.9214 
0.8434 
0.9482 
0.5473 
*Units are % HbA1c per year, adjusted only for antidiabetic medication, prednisolone use and 
BMI change. **Units are % HbA1c per year, adjusted for antidiabetic medication, prednisolone 
use and BMI change, age at diagnosis, gender, glucose toxicity, BMI, triglycerides and HDL. 
The values are expressed as the absolute difference in progression rate between the study 
group and the reference group. Positive values mean that the glycaemic deterioration rate is 
faster.   
  
  
Table 2: Characteristics at diagnosis of patients with type 2 diabetes by age category 
 Age at diagnosis (years)  
 <50 
 
50-60 
 
60-70 
 
>70 
 
P** 
(<50 vs >70 
N 823 1430 1820 1269  
Males 486(59.1%) 833(58.3%) 1028(56.5%) 666(52.5%) 0.0032 
BMI(kg/m2) 34.6(6.9) 32.7(6.2) 30.9(5.2) 29.1(4.4) <0.0001 
HbA1c(%) 8.2(1.8) 8.1(1.8) 8.0(1.9) 7.8(1.7) <0.0001 
Glucose toxicity  
 
320(38.9%) 509(35.6%) 590(32.4%) 349(27.5%) <0.0001 
HDL(mmol/L) 1.1(0.3) 1.2(0.3) 1.2(0.3) 1.3(0.3) <0.0001 
Triglycerides (mmol/L)* 2.6(1.7-4.0) 2.4(1.7-3.5) 2.3(1.6-3.1) 1.9(1.4-2.7) <0.0001 
Data are mean(sd) or N(%); * Median(IQR); **Comparison of patients was by t-test for 
continuous variables (triglycerides were log transformed)  and Chi-square for categorical
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FIGURE LEGENDS 
Figure 1 
Distribution of rate of glycaemic deterioration (increase in adjusted HbA1c per year 
characterised in % units). Patients with T2DM are represented in purple and LADA patients in 
green. 
Figure 2 
Mean (95%) rate of glycaemic deterioration (increase in adjusted HbA1c per year characterised 
in % units), by age at diagnosis. The number of patients in each age band is represented on the 
primary y-axis and the glycaemic deterioration rate is represented on the secondary y-axis. 
 
